Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis
Peritoneal carcinomatosis is considered a terminal stage of tumor progression.
Cytoreductive surgery plus aggressive combination intraperitoneal chemotherapy may
significantly alter the natural history of this disease. This study will define the maximum
tolerated dose of paclitaxel and 5-fluorouracil (5-FU) given as an early post-operative
intraperitoneal (IP) dwell therapy after cytoreductive surgery and continuous hyperthermic
peritoneal perfusion with cisplatin (CHPP).
Endpoint Classification: Safety Study, Primary Purpose: Treatment
United States: Federal Government
|National Cancer Institute (NCI)||Bethesda, Maryland 20892|